Navigation Links
Cancer Stem Cells Could Hold Key to Brain Tumor Therapy

Stem cell-like glioma cancer cells that share many characteristics with normal stem cells propel the lethal growth of brain cancers by promoting tumor blood vessel// formation, and may hold the key to treating these deadly cancers, a research team reported in the August 15th issue of Cancer Research.

Led by Jeremy Rich, M.D., associate professor at the Preston Robert Tisch Brain Tumor Center at Duke University, the researchers found that a small subset of glioma cells expressed higher levels of a growth factor associated with cancer cell growth. They believe this subset could be a target for new therapies against these intractable brain tumors.

Gliomas are the most common type of brain tumor, making up about half of all diagnosed primary (or non-metastatic) brain tumors. About 17,000 people in the United States are diagnosed with a primary brain tumor each year. Patients with the most aggressive glioma, called glioblastoma, have an average life expectancy of less than one year despite advances in cancer treatment. To better treat cancer patients, laboratories like those of Rich are trying to better understand the causes of tumor growth so that gliomas can be targeted with new drugs.

“Malignant brain tumors are highly lethal, despite aggressive surgery, radiation, and chemotherapy,” said Dr. Rich. “We believe targeting the cancer stem cells of brain tumors may offer a novel therapy that will help to decrease the blood supply feeding a growing tumor, and therefore decrease or stop that tumor’s growth.”

Researchers from other laboratories recently determined that a small fraction of all the cells in a glioma have special characteristics similar to brain stem cells. These stem cell-like glioma cells form tumors when implanted in animals. As the ability to form new blood vessels (called angiogenesis) to supply blood carrying nutrients is critical in cancer growth, Dr. Rich’s team studied if the formation of tumors by stem
'"/>




Page: 1 2

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
Breaking Medicine Technology:AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 1Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 2Uroplasty Reports First Fiscal Quarter Results 53547 1Uroplasty Reports First Fiscal Quarter Results 53547 2Uroplasty Reports First Fiscal Quarter Results 53547 3Uroplasty Reports First Fiscal Quarter Results 53547 4Uroplasty Reports First Fiscal Quarter Results 53547 5Uroplasty Reports First Fiscal Quarter Results 53547 6Uroplasty Reports First Fiscal Quarter Results 53547 7Uroplasty Reports First Fiscal Quarter Results 53547 8Uroplasty Reports First Fiscal Quarter Results 53547 9Uroplasty Reports First Fiscal Quarter Results 53547 10Uroplasty Reports First Fiscal Quarter Results 53547 11Uroplasty Reports First Fiscal Quarter Results 53547 12Uroplasty Reports First Fiscal Quarter Results 53547 13Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 1Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 2Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 3Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 4Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 5Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 6Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 7Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 8Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 9Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 53544 10